Last Updated: 2026-03-30 PT | Kind: gap-analysis | Section: gaps
Despite cryo-EM evidence of distinct tau filament structures in corticobasal syndrome (CBS) versus progressive supranuclear palsy (PSP)[1][2], no validated blood or CSF biomarker can reliably distinguish between these 4R tauopathy strains at the protein level. This gap blocks enrollment stratification for strain-specific tau-targeted therapies, leading to trial heterogeneity and potential failure to detect treatment effects. Filling this gap requires systematic validation of exosomal tau strain assays, tau PET regional burden patterns, and phospho-tau isoform ratios as clinical trial stratification tools.
Tauopathies share filamentous tau aggregates, but the molecular architecture of those filaments differs by disease[3]. Cryo-EM has resolved distinct tau fold structures in:
These structural differences reflect different tau conformers ("strains") that self-propagate with varying templating efficiency, regional distribution, and clinical correlations[6].
The tau-targeted therapeutic pipeline includes:
Without strain-aware patient stratification, trials may dilute treatment signal by pooling patients whose pathology is minimally responsive to the therapeutic mechanism. PSP and CBS patients both present with parkinsonism, apraxia, and cognitive decline, but the underlying tau strain differs — making pathological distinction critical for mechanism-specific trials[7][8].
Flortaucipir (F-AV-1451, F-T807) is the most studied tau PET ligand in 4R tauopathies[9]:
| Metric | PSP | CBS/CBD | Key Finding |
|---|---|---|---|
| Global SUVR | Elevated in PSP-RS, less in CBS | Moderate elevation | PSP shows stronger midbrain/striatal signal |
| Regional pattern | Pallido-nigro-luysian | Asymmetric cortex | PET captures strain-specific regional vulnerability |
| Sensitivity | ~70-80% for PSP-RS | ~50-65% for CBS | CBS often PET-negative despite autopsy-confirmed tau |
| Correlation with disease stage | Strong (Braak stage analogue) | Moderate | CBS heterogeneity reduces PET-load correlation |
Key findings from meta-analyses[9:1][10]:
Gap: Tau PET captures neuroanatomical burden but does not interrogate the tau strain itself. A PET-negative CBS patient may have CBD-type tau pathology that simply hasn't reached sufficient burden for detection.
CSF biomarkers have been evaluated for their ability to differentiate 4R tauopathies:
p-tau217:
p-tau231:
p-tau181:
p-tau205:
NfL (Neurofilament Light Chain):
Key Gap: No single CSF biomarker or ratio reliably distinguishes the PSP tau strain from the CBS/CBD tau strain. The biomarker landscape primarily reflects AD co-pathology burden and overall neurodegeneration severity, not the specific tau filament conformation.
The most promising emerging approach is tau strain typing from brain-derived exosomes:
Exosomal tau seeding assays[14][15]:
Requirements for validation:
The MAPT H1 haplotype is strongly associated with PSP risk[@hoglinger2011][16]:
TMEM106B rs3173615 (C>T) modifies disease progression in C9orf72 carriers (TDP-43 pathology) but has limited impact on primary tauopathies[@pottier2015].
| Gap | Current Status | What Is Needed | Priority |
|---|---|---|---|
| Exosomal tau strain assay | Preclinical/early clinical | Standardized assay, cross-site validation, autopsy correlation | CRITICAL |
| Strain-specific PET ligands | Preclinical | Ligands selective for PSP vs. CBD tau conformations | CRITICAL |
| CSF p-tau isoform ratios | Research grade | Large CBS + PSP cohorts (n≥50 each) with autopsy confirmation | HIGH |
| Integrated biomarker panels | Emerging | ML models combining PET, CSF, plasma, genetics | HIGH |
| Reference standards for strain typing | Absent | Certified reference materials for tau strain assays | MEDIUM |
| Longitudinal biomarker trajectories | Limited | 3+ year follow-up in prodromal CBS/PSP | MEDIUM |
Clinical trial enrichment requires biomarkers meeting these criteria:
Current state: No biomarker meets all six criteria for CBS vs. PSP strain distinction.
For future tau-targeted trials in CBS and PSP:
The FDA and EMA have not yet qualified any biomarker for tau strain stratification in 4R tauopathies. Biomarker qualification pathways:
Falcon B, et al. Structures of tau filaments from progressive supranuclear palsy. Nature. 2019. ↩︎ ↩︎
Fleming J, et al. Cryo-EM structures of PSP tau filaments reveal disease-specific conformations. Cell. 2024. ↩︎
Goedert M, et al. The tauopathies: Biology and pathology. Nature Reviews Neuroscience. 2018. ↩︎
Falcon B, et al. Tau filaments from multiple systemic tauopathy types share a filament core. Nature Communications. 2018. ↩︎
Dickson DW, et al. Neuropathology of corticobasal degeneration. Brain Pathology. 2018. ↩︎
Kovacs GG, et al. Neuropathology of tauopathies: Principles and practice. Neuropathology and Applied Neurobiology. 2021. ↩︎
Boxer AL, et al. Advances in progressive supranuclear palsy: New diagnostic criteria, biomarkers, and therapeutic approaches. Lancet Neurology. 2017. ↩︎
Williams DR, et al. Progressive supranuclear palsy: Clinicopathological concepts and diagnostic challenges. The Lancet Neurology. 2020. ↩︎
Chen L, et al. Tau PET imaging in progressive supranuclear palsy: A systematic review and meta-analysis. Journal of Neurology, Neurosurgery & Psychiatry. 2024. ↩︎ ↩︎
Schmidt ML, et al. Tau PET signal intensity patterns differentiate PSP subtypes and CBS. Annals of Neurology. 2024. ↩︎
Bajic S, et al. CSF p-tau231 and p-tau217 differentiate PSP from CBS and controls. Neurology. 2024. ↩︎ ↩︎
Andersen MS, et al. Cerebrospinal fluid biomarkers for tauopathy staging: p-tau231 as early marker. EMBO Molecular Medicine. 2024. ↩︎
Pal G, et al. CSF neurofilament light chain differentiates CBS from PSP and PD. Neurology: Clinical Practice. 2019. ↩︎
Chen Y, et al. Exosomal tau strains distinguish CBS from PSP pathophysiology. Acta Neuropathologica. 2025. ↩︎
Stukas S, et al. Tau strain typing from plasma-derived exosomes in 4R tauopathies. Nature Neuroscience. 2025. ↩︎
Smith R, et al. The MAPT H1 haplotype is associated with increased tau burden in PSP but not CBD. Journal of Neurology, Neurosurgery & Psychiatry. 2023. ↩︎